Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals (NASDAQ:QNRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Quoin Pharmaceuticals (NASDAQ:QNRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies [Yahoo! Finance]
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies